Core Insights - The Motley Fool aims to enhance the financial well-being of individuals by providing investment solutions and market analysis [1] Company Overview - Founded in 1993, The Motley Fool is a financial services company focused on making the world smarter, happier, and richer [1] - The company reaches millions of people monthly through various platforms, including premium investing solutions, free guidance, and market analysis on Fool.com [1] - The Motley Fool also produces top-rated podcasts and operates a non-profit organization, The Motley Fool Foundation [1]

Core Insights - Lantheus Holdings, Inc. is a leading company in the radiopharmaceutical sector, focused on improving patient outcomes through innovative solutions [3]. Company Information - Lantheus has been providing radiopharmaceutical solutions for over 65 years and is headquartered in Massachusetts, with additional offices in Canada and Sweden [3]. - The company is committed to enabling clinicians to Find, Fight, and Follow disease [3]. Upcoming Events - Lantheus management will present at several investor conferences, including: - B. Riley Securities Precision Oncology & Radiopharma Day in New York on February 28 [4]. - TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 2:30 pm ET [4]. - Leerink Global Healthcare Conference 2025 in Miami on March 11 at 1:40 pm ET [4]. - Live webcasts of the presentations will be available on the company's website, with replays accessible for at least 30 days [2].

Core Viewpoint - Lantheus Holdings, Inc. will host a conference call and webcast to discuss its financial and operating results for Q4 and the full year of 2024 on February 26, 2025 [1]. Group 1: Conference Call Details - The conference call and webcast will take place at 8:00 a.m. ET on February 26, 2025 [1]. - Participants can register online to access the conference call or webcast, with a recommendation to register fifteen minutes in advance to avoid delays [2]. - A replay of the webcast will be available approximately two hours after its completion and will be archived for at least 30 days [2]. Group 2: Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, focusing on delivering solutions that help clinicians in disease detection and management [3]. - The company has been providing radiopharmaceutical solutions for over 65 years and is headquartered in Massachusetts, with additional offices in Canada and Sweden [3].

Core Insights - Lantheus Holdings, Inc. is presenting real-world evidence of PYLARIFY's effectiveness in detecting recurrent prostate cancer at the 2025 ASCO Genitourinary Cancers Symposium [1][2] - PYLARIFY is the leading PSMA-targeted PET imaging agent in the U.S., with over 400,000 scans conducted across 48 states [3] Presentation Details - The presentation will occur on February 13, 2025, during two time slots: 11:25 am – 12:45 pm PT and 5:45 PM-6:45 PM PT [2] - The session will include two posters: one on early detection of recurrent prostate cancer and another on the role of conventional imaging and PYLARIFY in prostate cancer patients [2] Product Information - PYLARIFY (piflufolastat F 18) is a PSMA-targeted PET imaging agent that allows visualization of metastatic prostate cancer [3] - The recommended dose for PYLARIFY is 333 MBq (9 mCi), with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi) [3] Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, focused on improving patient outcomes through innovative diagnostic solutions [11]

Core Insights - Lantheus Holdings, Inc. announced the appointment of Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025, enhancing its leadership in radiopharmaceuticals [1][2] - Dr. Morrow brings extensive experience in oncology and drug development, which aligns with Lantheus' strategic initiatives and innovation efforts [2][3] - Following this appointment, the Board will consist of eleven directors, with nine being independent, reflecting a strong governance structure [1] Company Overview - Lantheus is a leading company focused on radiopharmaceuticals, dedicated to enabling clinicians to Find, Fight, and Follow disease for better patient outcomes [3] - The company has been providing radiopharmaceutical solutions for over 65 years and is headquartered in Massachusetts, with additional offices in Canada and Sweden [3]

Core Insights - Lantheus Holdings, Inc. has appointed Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025, enhancing its leadership in radiopharmaceuticals [1][2] - Dr. Morrow brings extensive experience in oncology and drug development, which aligns with Lantheus' strategic initiatives and innovation efforts [2][3] - Following this appointment, the Board will consist of eleven directors, with nine being independent, reflecting a strong governance structure [1] Company Overview - Lantheus is a leading company focused on radiopharmaceuticals, dedicated to enabling clinicians to Find, Fight, and Follow disease for improved patient outcomes [3] - The company has been providing radiopharmaceutical solutions for over 65 years and is headquartered in Massachusetts, with additional offices in Canada and Sweden [3]

Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, investors traded out of the niche healthcare stock, leaving it with a more than 7% loss on the day. That was in contrast with the S&P 500 index, which increased by 0.9%.New day, new dealWell before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Ev ...

Core Insights - Lantheus Holdings, Inc. has announced a definitive agreement to acquire Evergreen Theragnostics, Inc. for an upfront payment of $250 million and potential milestone payments of up to $752.5 million, enhancing its position in the radiopharmaceutical sector [2][7] - The acquisition is expected to solidify Lantheus' capabilities as a fully integrated radiopharmaceutical company, adding scalable manufacturing infrastructure and expanding its oncology diagnostic pipeline with the addition of OCTEVY, a diagnostic agent for neuroendocrine tumors [3][5] - Lantheus reaffirms its financial guidance for the full year and fourth quarter of 2024, projecting revenues between $1.51 billion and $1.52 billion and adjusted fully diluted EPS between $6.65 and $6.70 [8] Acquisition Details - The acquisition of Evergreen is aimed at enhancing Lantheus' manufacturing capabilities, particularly in radioligand therapy (RLT) and Contract Development and Manufacturing (CDMO) services, which will support long-term growth and mitigate third-party risks [5][6] - OCTEVY, a registrational-stage diagnostic imaging agent, is expected to complement Lantheus' therapeutic candidate PNT2003, potentially being used as a theranostic pair for treating neuroendocrine tumors [5][6] - The transaction has been approved by the Boards of Directors of both companies and is expected to close in the second half of 2025, pending regulatory clearances [7] Strategic Rationale - The acquisition is positioned as a strategic move to enhance Lantheus' operational capabilities across the radiopharmaceutical value chain, allowing for better patient outcomes through improved manufacturing and development processes [4][5] - Evergreen's expertise in drug discovery and early-stage clinical development is expected to enrich Lantheus' oncology pipeline and accelerate the delivery of innovative therapies to patients [4][5] - The integration of Evergreen's team and capabilities is anticipated to foster a culture focused on developing new solutions for cancer patients, aligning with Lantheus' mission [4][6]

Acquisition Overview - Lantheus Holdings Inc announced a definitive agreement to acquire Life Molecular Imaging Ltd in an all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments [1] - The transaction is expected to close in the second half of 2025, subject to customary closing conditions including regulatory approvals [6] - The acquisition is expected to be accretive to Lantheus' Adjusted Earnings Per Share within 12 months of close [2] Strategic Rationale - The acquisition establishes a commercial Alzheimer's disease (AD) franchise with the addition of Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease [1][2] - Life Molecular brings robust R&D capabilities, a strong commercial infrastructure, and an established international presence, which Lantheus plans to utilize to accelerate the development and commercialization of the combined company's pipeline [2] - The acquisition complements Lantheus' pipeline with the addition of highly complementary radiodiagnostic clinical-stage assets targeting diseases with significant unmet needs [4] Financial Impact - The transaction is expected to immediately enhance Lantheus' near and long-term growth profile [2] - Lantheus expects to maximize access to Neuraceq for the approximately 55 million people around the world who are living with AD or mild cognitive impairment [4] - The acquisition builds on Lantheus' June 2024 acquisition of the global rights to LMI's clinical-stage radiotherapeutic and radiodiagnostic pair, 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2, which target gastrin-releasing peptide receptor (GRPR) for prostate, breast and other cancers [5] Product Details - Neuraceq is indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline [13] - The overall safety profile of Neuraceq is based on data from 1,090 administrations of Neuraceq to 872 subjects, with no serious adverse reactions reported [10] - Neuraceq is commercially approved in the United States, Canada, Europe, the UK, Switzerland, China, Japan, South Korea, and Taiwan [20] Company Background - Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes [15] - Life Molecular Imaging is a global radiopharmaceutical company dedicated to developing and offering novel cutting-edge radiopharmaceuticals that improve early detection and characterization of chronic and life-threatening diseases [19] - Life Healthcare, the parent company of Life Molecular, is a global people-centered, diversified healthcare organization with over 40 years' experience in the South African private healthcare sector [11]

Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease Advances Lantheus' radiopharmaceutical leadership with addition of Alzheimer's radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities Transaction expected to be accretive to adjusted EPS within the first 12 months Company to host conference call on January 13, 2025, at 8:30 AM EST BEDFORD, Mass., Ja ...